Activity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with ketoconazole (keto): A prospective phase II study from the Prostate Cancer Clinical Trials Consortium

Autor:	Charles J. Ryan, Arturo Molina, Terence W. Friedlander, Rahul Aggarwal, Lawrence Fong, Gerald J. Fetterly, Li Zhang, Eric J. Small, Vivian Weinberg, John Wilton, Won Kim, Russell Z. Szmulewitz, James L. Mohler, Jeffrey Bozeman, Andrew C. Hsieh, Amy M. Lin, Allison Morse
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Abiraterone acetate Phases of clinical research Castration resistant medicine.disease Clinical trial chemistry.chemical_compound Prostate cancer Androgen synthesis Endocrinology chemistry Internal medicine medicine lipids (amino acids peptides and proteins) Ketoconazole business Previously treated medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:5039-5039
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.5039
Popis:	5039 Background: AA, like keto, inhibits CYP17, the rate-limiting enzyme in androgen synthesis. Since pts with prior keto were excluded from the pivotal phase III AA trials, the utility of AA follo...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c8cee6441e3636a71374b3bcb6cd3d61 https://doi.org/10.1200/jco.2014.32.15_suppl.5039 Zobrazit plný text záznamu